Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:55:42 EDT Thu 09 May 2024
Enter Symbol
or Name
USA
CA



Q:RPTX - REPARE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RPTX - Q0.53.60·3.980.33.79+0.5115.54,588.015,02117,0153.88  3.96  3.559913.85  2.9819:59:55May 0715 min RT 2¢

Recent Trades - Last 10 of 17015
Time ETExPriceChangeVolume
19:59:55Q3.680.40400
19:57:45Q3.680.4058
19:53:26Q3.700.424
19:47:30Q3.700.42201
19:46:47Q3.700.4210
19:30:28Q3.7190.4391
18:58:31Q3.710.4320
18:54:41Q3.720.4486
18:46:17Q3.71990.439910
18:46:00Q3.71880.43881

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-07 16:49U:RPTXSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-05-07 16:05U:RPTXNews ReleaseRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
2024-04-30 07:05U:RPTXNews ReleaseRepare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
2024-04-30 07:05U:RPTXNews ReleaseDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
2024-04-26 16:05U:RPTXNews ReleaseRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
2024-02-29 07:05U:RPTXNews ReleaseRepare Therapeutics to Participate in Two Upcoming Investor Conferences
2024-02-28 15:58U:RPTXSEDAR Annual Information FormSEDAR Annual Report
2024-02-28 15:01U:RPTXSEDAR Audited Annual Financial StatementsSEDAR MD & A
2024-02-28 07:05U:RPTXNews ReleaseRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-15 07:05U:RPTXNews ReleaseRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
2024-02-12 16:05U:RPTXNews ReleaseRepare Therapeutics to Regain Global Rights to Camonsertib
2024-01-25 07:00U:RPTXNews ReleaseRepare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
2024-01-08 07:00U:RPTXNews ReleaseRepare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
2024-01-04 16:05U:RPTXNews ReleaseRepare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
2023-12-29 16:05U:RPTXNews ReleaseRepare Therapeutics Insiders Establish Automatic Securities Disposition Plans
2023-11-15 07:00U:RPTXNews ReleaseRepare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Ž ¸ Inhibitor
2023-11-09 11:30U:RPTXSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-09 11:28U:RPTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 07:00U:RPTXNews ReleaseRepare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-07 07:00U:RPTXNews ReleaseRepare Therapeutics to Host Investor and Analyst Conference Call and Webcast